Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release alternatives to currently approved drugs.
Eupraxia Pharmaceuticals has raised $63.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2026.
Eupraxia Pharmaceuticals's investors include Silicon Valley Bank, Yabema Capital.
Eupraxia Pharmaceuticals is headquartered in Victoria, Canada.
Eupraxia is a clinical-stage biotech company developing locally delivered, extended-release alternatives to currently approved drugs.
Eupraxia Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Eupraxia Pharmaceuticals — Funding & Investors." VCBacked, February 19, 2026, https://www.vcbacked.co/company/eupraxia-pharmaceuticals. Accessed August 13, 2026.
VCBacked. (2026). Eupraxia Pharmaceuticals — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/eupraxia-pharmaceuticals
{{cite web |title=Eupraxia Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/eupraxia-pharmaceuticals |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated